Glecaprevir/Pibrentasvir

Form: Oral tablets

Strength: Glecaprevir 100 mg Pibrentasvir 40 mg

Reference Brands: Mavyret®,

Category: Hepatitis

Glecaprevir/Pibrentasvir is a fixed-dose, pan-genotypic antiviral combination used in the treatment of chronic Hepatitis C virus (HCV) infection across genotypes 1 through 6. Marketed as Mavyret® in the US and EU by AbbVie, it combines Glecaprevir, an NS3/4A protease inhibitor, and Pibrentasvir, an NS5A inhibitor, to deliver a highly effective once-daily oral regimen. Approved by the FDA and EMA, it is indicated for use in adults and pediatric patients (≥3 years), with or without cirrhosis. Glecaprevir/Pibrentasvir is widely used in pharma B2B for short-duration (typically 8–12 weeks) HCV treatment strategies across global markets.